Genitourinary System Neoplasm

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1 and 5637). The variant is located in the Extracellular II domain. RT112 cells infected with lentiviral vec… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found in patient's that were diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013, CF0943, CF0945, CF1005, CF0955). Th… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell lines (DSH1 and 5637). The variant is located in the Extracellular II domain. In regards to the response to lapatinib… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variants were found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013). The patient was categorised a… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBI). The variant is located in the transmembrane domain. RT112 cells infected with lentiviral vectors cont… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBI). The variant is located in the transmembrane domain. Regarding the response to lapatinib, after three d… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID:CF0940). The patient was categorised as a “… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID:CF0977). The patient was categorised as a “… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis.

PMID 26162296 · Klatte et al., 2015 · Open in CIViC

Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.

PMID 26162296 · Klatte et al., 2015 · Open in CIViC

Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all ha… (full text at CIViC)

PMID 30797591 · Mesquita et al., 2019 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0959). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

This study assessed the potential for mutated genes associated with urothelial bladder cancers as candidates for platinum-based neoadjuvant therapy. Nineteen patients (18 male, 3 female) diagnosed wit… (full text at CIViC)

PMID 32984035 · Hirotsu et al., 2020 · Open in CIViC

This study assessed the potential for mutated genes associated with urothelial bladder cancers as candidates for platinum-based neoadjuvant therapy. Nineteen patients (18 male, 3 female) diagnosed wit… (full text at CIViC)

PMID 32984035 · Hirotsu et al., 2020 · Open in CIViC

Variant found in patients that were diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0949, CF0982, CF3098). Th… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0950). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0979). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF1005). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

In uterine tumors resembling ovarian sex cord tumor (UTROSCT; n = 4), RNA sequencing identified recurrent ESR1::NCOA3 (n = 2), ESR1::NCOA2 (n = 1), and GREB1::NCOA2 (n = 1) fusions, involving NCOA2/3 … (full text at CIViC)

PMID 30273195 · Dickson et al., 2019 · Open in CIViC

In a retrospective UTROSCT cohort (n = 17, follow-up n = 13), 3 patients (23.1%) carrying GREB1::NCOA2, ESR1::NCOA3 or ESR1::CITED2 fusions developed pelvic, abdominal or pulmonary recurrence, with re… (full text at CIViC)

PMID 38000680 · Qijun et al., 2024 · Open in CIViC

In a clinical study including 144 patients, nuclear beta-2 expression is significantly correlated with decreased RFS (p < 0.01), decreased MFS (p < 0.01) and PSA failure (p < 0.01). Moreover cytoplasm… (full text at CIViC)

PMID 20501637 · Leung et al., 2010 · Open in CIViC

Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.04… (full text at CIViC)

PMID 25544710 · Qi et al., 2015 · Open in CIViC

EML6::NTRK3 fusion is seen in cases of Infantile fibrosarcoma and congenital mesoblastic nephroma. In general, these types of tumors more commonly harbor ETV6::NTRK3 fusions.

PMID 29099503 · Church et al., 2018 · Open in CIViC

A frequent genetic alteration in congenital mesoblastic nephroma is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusivel… (full text at CIViC)

PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC

In a group of 111 mesoblastic nephroma (MN) samples, 79 were were evaluable by FISH, which consisted of 38 classical MN, 29 cellular MN, and 12 mixed MN samples. 5 year relapse free survival (RFS) was… (full text at CIViC)

PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC

A patient with prostate cancer with exceptional response to treatment was identified who harbored a somatic hemizygous deletion of the DNA repair gene FANCA and putative partial loss of function of th… (full text at CIViC)

PMID 26181256 · Beltran et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-depende… (full text at CIViC)

PMID 24253377 · Okazaki et al., 2014 · Open in CIViC

243 primary PCa, 37 metastatic PCa, and 20 castration-resistant PCa (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the major… (full text at CIViC)

PMID 26891277 · Yu et al., 2016 · Open in CIViC

In a retrospective study, the association between biomarker and prognosis in patients with advanced ovarian cancer were evaluated. High expression FGFR4 or FGF19 were associated with poor overall surv… (full text at CIViC)

PMID 26323668 · Hu et al., 2015 · Open in CIViC

Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated wi… (full text at CIViC)

PMID 27870574 · Nogova et al., 2017 · Open in CIViC

FGFR1 expression was increased in urothelial carcinoma cell lines and patient tumours, independent of stage and grade. FGFR1 knockdown resulted in decreases proliferation and survival in some of the c… (full text at CIViC)

PMID 19458078 · Tomlinson et al., 2009 · Open in CIViC

One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors (SU5402, TKI258 or PD173074). IC50 values for PD173074 and TKI-258 (Dovitinib) were in n… (full text at CIViC)

PMID 21119661 · Lamont et al., 2011 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Two types of UC cell lines were compared in this study. T24 and J82 which are mesenchymal subtype and overexpress FGFR1, and RT-4 and UMUC-14, epithelial subtype which do not express FGFR1. T24 and J8… (full text at CIViC)

PMID 30326563 · Kim et al., 2018 · Open in CIViC

Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC)

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 2 urothelial ca… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

patients with FGFR2 mutations had a much higher incidence of progression (32/125, 26%) whereas among those with wild type where only (120/848,14%) displayed incidences of progression. The mutated FGFR… (full text at CIViC)

PMID 28314589 · Jeske et al., 2017 · Open in CIViC

Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC)

PMID 24448819 · Eritja et al., 2014 · Open in CIViC

The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wi… (full text at CIViC)

PMID 18757403 · Byron et al., 2008 · Open in CIViC

Only 12/118(10.2%) of patients with type I papillary renal cell carcinoma expressed FGFR2 whereas 37/96 (38.5%) patients with type II papillary renal cell carcinoma(P=0.001). In addition, FGFR2 expre… (full text at CIViC)

PMID 27379982 · Tsimafeyeu et al., 2017 · Open in CIViC

In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC)

PMID 31340094 · Loriot et al., 2019 · Open in CIViC

Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and incre… (full text at CIViC)

PMID 23558953 · Wu et al., 2013 · Open in CIViC